Clinical Study On Intravitreal VEGF Inhibitors For Retinal Arterial Macroaneurysm

Objective : To investigate the effectiveness of intravitreal VEGF inhibitors for retinal arterial microaneurysm(RAM).Methods:This prospective study selected 25 eyes of 25 patients with symptomatic RAM,diagnosed by fundus examination,optical coherence tomography(OCT)and fundus fluorescein angiography(FFA)and indocyanine green angiography(ICGA)from April 2018 to November 2019.All these patients received intravitreal injection of VEGF inhibitors(Ranibizumab or Conbercept 0.5mg/0.05ml),and were followed up at 2,4,8 and 12 weeks after treatment to observe the best corrected visual acuity(BCVA),central macular thickness(CMT),the tumor size and the difference between the Conbercept and Ranibizumab treatment group.Results:In this study,all the 25 patients were followed up at 2,4,8 and 12 weeks after intravitreal VEGF inhibitor injection.After treatment,all the RAM tumors were gradually shrunk,the macular hemorrhage and edema were gradually absorbed,and no reaggravation of macular hemorrhage and edema was observed.No complications of intravitreal injection occurred in these 25 cases.BCVA gradually increased from 2 weeks after treatment and there were statistically significant differences on BCVA at each observation point after treatment compared with those of before treatment(P < 0.05).CMT gradually decreased from 2 weeks after treatment,but there was no statistically significant difference between CMT of 2 weeks after treatment and before treatment(P=0.123).And there were statistically significant differences between CMT at each observation point after 4 weeks of treatment and before treatment(P < 0.05).In this study,17 eyes were treated with Conbercept and 8 eyes were treated with Ranibizumab.There were no statistically significant differences in the improvement of BCVA and reduction of CMT in the two groups at each observation point(P>0.05).Conclusion:For symptomatic retinal arterial microaneurysm patients,intravitreal injection of VEGF inhibitors may significantly improve BCVA and reduce CMT of the affected eye,and the tumor size become smaller gradually after treatment.There were no statistically significant differences on BCVA improvement and CMT reduction between Conbercept and Ranibizumab groups.